HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience [Seeking Alpha]
Cybin Inc. (HELP)
Company Research
Source: Seeking Alpha
Key 2026 catalysts include Phase 3 data for HLP003 in major depressive disorder and Phase 2 data for HLP004 in generalized anxiety disorder. HELP's cash burn accelerated to $36.7M in 3Q26, with $195M cash on hand and a $100M ATM facility providing runway through pivotal trial milestones. Valuation remains binary and catalyst-driven, with enterprise value below cash, reflecting market caution on clinical and regulatory risk. SDI Productions/E+ via Getty Images Thesis: New Ticker to Signal Change As you know, when I last converged HELUS Pharma ( HELP ), we referred to it as Cybin. Since then, the company has formally transitioned at the start of January this year, when This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation
Show less
Read more
Impact Snapshot
Event Time:
HELP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HELP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HELP alerts
High impacting Cybin Inc. news events
Weekly update
A roundup of the hottest topics
HELP
News
- Cybin (HELP) had its price target raised by HC Wainwright from $55.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory CommitteeGlobeNewswire
- Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers [Yahoo! Finance]Yahoo! Finance
HELP
Earnings
- 2/13/26 - Miss
HELP
Sec Filings
- 2/24/26 - Form 6-K
- 2/18/26 - Form 6-K
- 2/17/26 - Form SCHEDULE
- HELP's page on the SEC website